Research Output per year
Research Output per year
Personal profile
Research interests
My primary research interest is to develop and conduct phase I and II clinical trials with novel agents for patients with newly diagnosed or relapsed lung cancer. I am also interested in clinical trial methodology and medical education.
Areas of Clinical Interest
Thoracic oncology, lung cancer
Fingerprint
Dive into the research topics where Maria Baggstrom is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 17 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output
-
Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy
Arnold, S. M., Chansky, K., Baggstrom, M. Q., Thompson, M. A., Sanborn, R. E., Villano, J. L., Waqar, S. N., Hamm, J., Leggas, M., Willis, M., Rosales, J. & Crowley, J. J., Jan 1 2020, (Accepted/In press) In: Clinical Lung Cancer.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
Stinchcombe, T. E., Jänne, P. A., Wang, X., Bertino, E. M., Weiss, J., Bazhenova, L., Gu, L., Lau, C., Paweletz, C., Jaslowski, A., Gerstner, G. J., Baggstrom, M. Q., Graziano, S., Bearden, J. & Vokes, E. E., Oct 2019, In: JAMA oncology. 5, 10, p. 1448-1455 8 p.Research output: Contribution to journal › Article › peer-review
12 Scopus citations -
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Sequist, L. V., Gray, J. E., Harb, W. A., Lopez-Chavez, A., Doebele, R. C., Modiano, M. R., Jackman, D. M., Baggstrom, M. Q., Atmaca, A., Felip, E., Provencio, M., Cobo, M., Adiwijaya, B., Kuesters, G., Kamoun, W. S., Andreas, K., Pipas, J. M., Santillana, S., Cho, B. C., Park, K. & 1 others, , 2019, In: Oncologist. 24, 8, p. 1095-1102 8 p.Research output: Contribution to journal › Article › peer-review
7 Scopus citations -
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)
Baggstrom, M. Q., Socinski, M. A., Wang, X. F., Gu, L., Stinchcombe, T. E., Edelman, M. J., Baker, S., Feliciano, J., Novotny, P., Hahn, O., Crawford, J. A. & Vokes, E. E., May 2017, In: Journal of Thoracic Oncology. 12, 5, p. 843-849 7 p.Research output: Contribution to journal › Article › peer-review
Open Access12 Scopus citations -
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)
Arnold, S. M., Chansky, K., Leggas, M., Thompson, M. A., Villano, J. L., Hamm, J., Sanborn, R. E., Weiss, G. J., Chatta, G. & Baggstrom, M. Q., Oct 1 2017, In: Investigational New Drugs. 35, 5, p. 608-615 8 p.Research output: Contribution to journal › Article › peer-review
Open Access11 Scopus citations